Galapagos 9M25 results hold no surprises, new outlook following cell Tx winddown
Galapagos reported 9M25 results with a cash position of € 3,050m (YE24: € 3,317.8m) and an updated outlook, where it expects to end FY25 with € 2,975- € 3,025m in cash, and to incur costs of € 250-325m related to the winddown of the cell therapy business. Looking ahead, the company will focus its strategy on building a new pipeline through BD, and more information on BD strategy will be provided during this afternoon's conference call. € 37 TP and ACCUMULATE maintained.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.